Whether it is a newly started biotechnology R&D company or a multinational pharmaceuticals group, a venture’s commercial success depends on the legal safeguards it has to protect its intellectual property rights and to take action when they are threatened – for example by patent infringement or impermissible parallel imports.
Structural M&A and financing are important issues in the biotechnology and pharmaceuticals industries. With significant transactions experience and specific knowledge of the commercial conditions in the sector, Vinge’s specialists can perform transactions quickly, efficiently and to the highest standard.
Acquisitions in these industries can be affected by the fact that the target is not a trading company but a research and development enterprise charged with producing future products. This puts particular demands on constructing the relevant contracts.
Vinge’s lawyers have the specialist knowledge of the regulatory issues needed for each industry.
‘Vinge has a great ability to provide the right team of lawyers to ensure that the client is provided with the highest standard of expertise in the various legal areas involved, while maintaining simple and effective communication with the client.’ Legal 500 2022